Back to top

AstraZeneca Advances BRAVO Trial for AZD2389 in Advanced Liver Fibrosis

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new BRAVO study, officially titled “A Phase IIa, Rando...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)